7
www.epmmagazine.com
SECURES €25 MILLION its research and development and help target commercialisation for its diagnostic tests and platforms. Tuomas Tenkanen, CEO of Mobidiag, said: "This EIB loan is a further validation of Mobidiag’s progress as we become a leading player in the molecular diagnostics market providing innovative and differentiated solutions that are adopted by key laboratories throughout Europe. Following extensive R&D and clinical validation, we are
proud that our stateof-the-art technology is now commercially available internationally. This loan will allow us to accelerate the development of the Mobidiag platform content to the next level, and build significant value over the coming years by building a comprehensive portfolio of diagnostics tests that can be used on our devices. We are delighted to have the EIB’s support and look forward to working with them again.”
Private equity firm acquires CDMO
P
rivate equity firm Ampersand Capital Partners has announced it will acquire contract development and manufacturing organisation (CMDO) Vibalogics.
mature cell type into another. Dr Darrin M. Disley, CEO, Mogrify, said: “We are growing a world-class scientific and executive team that will enable Mogrify to become a global leader in the development of novel cell conversion IP that underpins the
development of lifesaving cell therapies. The new Bio-Innovation Centre at the Cambridge Science Park offers outstanding facilities, service and networks to its tenants and we’re thrilled to be joining them at this exciting time.”
Vibalogics focuses on complex live biological products and offers a range of services including process development, manufacturing and fill and finish of products for biopharmaceutical companies developing oncolytic viral therapies, gene therapies, and vaccines. Ampersand will invest in expanding Vibalogics’ capabilities to meet increasing industry demand for the development
and manufacturing of complex viral products. Stefan Beyer, CEO of Vibalogics said: “With the benefit of Ampersand as our partner, Vibalogics will now strengthen and expand its position in the US and European markets while further investing in additional process development and GMP manufacturing capabilities. The partnership solidifies Vibalogics’ existing presence in the biologics manufacturing space and will allow the company to continue to exceed our customers’ expectations by facilitating the development of innovative therapeutic approaches that significantly improve the treatment of patients suffering from cancer
and genetic disorders. We are very pleased to have Ampersand on board as we take Vibalogics through to its next phase of growth.” David Anderson, general partner at Ampersand said: “Vibalogics is a leading company in its field. Given the exciting developments within the complex virus market this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company. We are looking forward to working with the team at Vibalogics to accelerate and continue its success in delivering cutting edge therapies to patients in need.”